Refractory intracranial hypertension in posterior reversible encephalopathy syndrome

Neurocritical Care

Volumn 19, Issue 3, 2013, Pages 376-380

  Facchini, Alberto ^a,b   Magnoni, Sandra ^b   Civelli, Vittorio ^b   Triulzi, Fabio ^b   Nosotti, Mario ^a,b   Stocchetti, Nino ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Barbiturate; Immunosuppressive agents; Intracranial hypertension; Lung transplantation; Reversible posterior leukoencephalopathy syndrome; Status epilepticus

Indexed keywords

AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CYCLOSPORIN; DIAZEPAM; ETIRACETAM; HYPERTONIC SOLUTION; MANNITOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PREDNISONE; PROPOFOL; TACROLIMUS; THIOPENTAL; THYMOCYTE ANTIBODY; VASOPRESSIN DERIVATIVE;

ACINETOBACTER INFECTION; ADULT; ANISOCORIA; ARTICLE; ARTIFICIAL VENTILATION; BRAIN DAMAGE; BRAIN EDEMA; BRAIN HERNIA; BRONCHIECTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CRANIAL NERVE PARALYSIS; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; GAZE; GLASGOW COMA SCALE; HEADACHE; HUMAN; HYPERTENSIVE CRISIS; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; INTRACRANIAL PRESSURE MONITORING; LIMB WEAKNESS; LONG TERM CARE; LUNG TRANSPLANTATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; TONIC CLONIC SEIZURE; TRANSDUCER; UROSEPSIS;

ADULT; ANTILYMPHOCYTE SERUM; BARBITURATES; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; IMMUNOSUPPRESSIVE AGENTS; INTRACRANIAL PRESSURE; MYCOPHENOLIC ACID; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; THIOPENTAL; TREATMENT OUTCOME;

EID: 84890460152     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-013-9852-z     Document Type: Article

References (23)

1. Liman TG, Bohner G, Heuschmann PU, Endres M, Siebert E. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol. 2012;259:155-64.
2. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR. 2008;29:1043-9.
3. Prasad G, Gulati S, Gupta RK, Kumar R, Sharma K, Sharma RK. Is reversible posterior leukoencephalopathy with severe hypertension completely reversible in all patients? Pediatr Nephrol. 2003;18(11):1161-6.
4. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR. 2008;29:1036-42.
5. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR. 2002;23:1038-48.
6. Li Y, Gor D, Walicki D, et al. Spectrum and potential pathogenesis of reversible posterior leukoencephalopathy syndrome. J Stroke Cerebrovasc Dis. 2012;21(8):873-82.
7. Filler G. Calcineurin inhibitors in pediatric renal transplant recipients. Paediatr Drugs. 2007;9:165-74.
8. Emre S, Genyk Y, Schluger LK, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int. 2000;13:73-8.
9. Jain A, Brody D, Hamad I, Rishi N, Kanal E, Fung J. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. Transplantation. 2000;69(1):172-6.
10. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13:313-26.
11. Wu Q, Marescaux C, Wolff V, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol. 2010;64:169-77.
12. Rosso L, Nosotti M, Mendogni P, et al. Lung transplantation and posterior reversible encephalopathy syndrome: a case series. Transplant Proc. 2012;44:2022-5.
13. Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant. 2004;23(5):632-8.
14. Moskowitz A, Nolan C, Lis E, Castro-Malaspina H, Perales MA. Posterior reversible encephalopathy syndrome due to sirolimus. Bone Marrow Transplant. 2007;39:653-4.
15. Pedraza R, Marik PE, Varon J. Posterior reversible encephalopathy syndrome: a review. Crit Care Shock. 2009;12:135-43.
16. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury. VI. Indications for intracranial pressure monitoring. J Neurotrauma. 2007;24(Suppl 1):S37-44.
17. Fitzgerald-Hines J, King ML. Posterior reversible encephalopathy syndrome: a case study. J Neurosci Nurs. 2006;38:338-41.
18. Lee VH, Temes RE, John S, Conners JJ, Bleck T, Prabhakaran S. Posterior reversible leukoencephalopathy syndrome presenting with global cerebral edema and herniation. Neurocrit Care. 2013;18:81-3.
19. Vavilala MS. Intracranial pressure monitoring in meningitis: thinking beyond traumatic brain injury. Pediatr Crit Care Med. 2011;12(6):689-90.
20. Vavilala MS, Lam AM. Intraoperative intracranial pressure monitoring in pneumococcal meningitis. Anesth Analg. 2000;90:107-8.
21. Bacher A. Intracranial hypertension in fulminant hepatic failure. Transplant Proc. 2006;38:783-5.
22. Dunn LT. Raised intracranial pressure. J Neurol Neurosurg Psychiatry. 2002;73(Suppl 1):i23-7.
23. Stocchetti N. Evidence for intracranial pressure monitoring: a very demanding challenge. Neurosurgery. 2012;71(6):E1210-1.